@article{4275f182272149a3a27cc79460481173,
title = "Missense variants in TAF1 and developmental phenotypes: Challenges of determining pathogenicity",
abstract = "We recently described a new neurodevelopmental syndrome (TAF1/MRXS33 intellectual disability [ID] syndrome) (MIM# 300966) caused by pathogenic variants involving the X-linked gene TATA-box binding protein associated factor 1 (TAF1), which participates in RNA polymerase II transcription. The initial study reported 11 families, and the syndrome was defined as presenting early in life with hypotonia, facial dysmorphia, and developmental delay that evolved into ID and/or autism spectrum disorder. We have now identified an additional 27 families through a genotype-first approach. Familial segregation analysis, clinical phenotyping, and bioinformatics were capitalized on to assess potential variant pathogenicity, and molecular modeling was performed for those variants falling within structurally characterized domains of TAF1. A novel phenotypic clustering approach was also applied, in which the phenotypes of affected individuals were classified using 51 standardized Human Phenotype Ontology terms. Phenotypes associated with TAF1 variants show considerable pleiotropy and clinical variability, but prominent among previously unreported effects were brain morphological abnormalities, seizures, hearing loss, and heart malformations. Our allelic series broadens the phenotypic spectrum of the TAF1/MRXS33 ID syndrome and the range of TAF1 molecular defects in humans. It also illustrates the challenges for determining the pathogenicity of inherited missense variants, particularly for a gene mapping to chromosome X.",
keywords = "Cornelia de Lange, MRXS33 intellectual disability syndrome, TAF1, exome sequencing, transcriptomopathy",
author = "Hanyin Cheng and Simona Capponi and Emma Wakeling and Elaine Marchi and Quan Li and Mengge Zhao and Chunhua Weng and Stefan, {Piatek G.} and Helena Ahlfors and Robert Kleyner and Alan Rope and Aim{\'e} Lumaka and Prosper Lukusa and Koenraad Devriendt and Joris Vermeesch and Posey, {Jennifer E.} and Palmer, {Elizabeth E.} and Lucinda Murray and Eyby Leon and Jullianne Diaz and Lisa Worgan and Amali Mallawaarachchi and Julie Vogt and {de Munnik}, {Sonja A.} and Lauren Dreyer and Gareth Baynam and Lisa Ewans and Zornitza Stark and Sebastian Lunke and Gon{\c c}alves, {Ana R.} and Gabriela Soares and Jorge Oliveira and Emily Fassi and Marcia Willing and Waugh, {Jeff L.} and Laurence Faivre and Riviere, {Jean Baptiste} and Sebastien Moutton and Shehla Mohammed and Katelyn Payne and Laurence Walsh and Amber Begtrup and {Guillen Sacoto}, {Maria J.} and Ganka Douglas and Nora Alexander and Buckley, {Michael F.} and Mark, {Paul R.} and Ad{\`e}s, {Lesley C.} and Sandaradura, {Sarah A.} and Lupski, {James R.} and Tony Roscioli and Agrawal, {Pankaj B.} and Kline, {Antonie D.} and Kai Wang and Timmers, {H. T.Marc} and Lyon, {Gholson J.}",
note = "Funding Information: This study was supported by funds from the Stanley Institute for Cognitive Genomics at Cold Spring Harbor Laboratory (G. J. L.) and the New York State Office for People With Developmental Disabilities at the Institute for Basic Research in Developmental Disabilities (IBR) in Staten Island, NY (G. J. L.). The DDD study presents independent research commissioned by the UK Health Innovation Challenge Fund (Grant #HICF-1009-003), a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute (Grant #WT098051). L. E. thanks the Genome. One clinical team for their assistance with sequencing. S. C. was supported through a research grant from the CC-XDP consortium to H. T. M. T. H. T. M. T. acknowledges financial support by the Deutsche Forschungsgemeinschaft (SFB850 and SFB992). G. B. and the Undiagnosed Diseases Program WA are supported by the Angela Wright Bennett Foundation and the McCusker Charitable Foundation. This study was jointly funded by the United States National Human Genome Research Institute (NHGRI), a National Heart, Lung, and Blood Institute (NHLBI) grant to the Baylor-Hopkins Center for Mendelian Genomics (J. R. L., UM1 HG006542), and the National Institute of Neurological Disorders and Stroke (J. R. L., R35 NS105078). J. E. P. is supported by NHGRI K08 HG008986. K. W., M. Z., and C. W. are supported by NIH grant LM012895. Individuals from family 17 were tested as part of the Australia EPIC-ID study, and Individual 21 was tested as part of the Australian Genomics Acute Care Flagship (National Health and Medical Research Council GNT1113531). The authors extend their appreciation to the families and clinicians who contributed to this paper. G. J. L. thanks Melissa Nashat and Vicky Brandt for providing critical comments on the manuscript. This study makes use of data generated by the DECIPHER community. A full list of centers who contributed to the generation of the data is available from http://decipher.sanger.ac.uk and via email from decipher@sanger.ac.uk. Funding for the project was provided by the Wellcome Trust. Funding Information: This study was supported by funds from the Stanley Institute for Cognitive Genomics at Cold Spring Harbor Laboratory (G. J. L.) and the New York State Office for People With Developmental Disabilities at the Institute for Basic Research in Developmental Disabilities (IBR) in Staten Island, NY (G. J. L.). The DDD study presents independent research commissioned by the UK Health Innovation Challenge Fund (Grant #HICF‐1009‐003), a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute (Grant #WT098051). L. E. thanks the Genome. One clinical team for their assistance with sequencing. S. C. was supported through a research grant from the CC‐XDP consortium to H. T. M. T. H. T. M. T. acknowledges financial support by the Deutsche Forschungsgemeinschaft (SFB850 and SFB992). G. B. and the Undiagnosed Diseases Program WA are supported by the Angela Wright Bennett Foundation and the McCusker Charitable Foundation. This study was jointly funded by the United States National Human Genome Research Institute (NHGRI), a National Heart, Lung, and Blood Institute (NHLBI) grant to the Baylor‐Hopkins Center for Mendelian Genomics (J. R. L., UM1 HG006542), and the National Institute of Neurological Disorders and Stroke (J. R. L., R35 NS105078). J. E. P. is supported by NHGRI K08 HG008986. K. W., M. Z., and C. W. are supported by NIH grant LM012895. Individuals from family 17 were tested as part of the Australia EPIC‐ID study, and Individual 21 was tested as part of the Australian Genomics Acute Care Flagship (National Health and Medical Research Council GNT1113531). The authors extend their appreciation to the families and clinicians who contributed to this paper. G. J. L. thanks Melissa Nashat and Vicky Brandt for providing critical comments on the manuscript. This study makes use of data generated by the DECIPHER community. A full list of centers who contributed to the generation of the data is available from http://decipher.sanger.ac.uk and via email from decipher@sanger.ac.uk . Funding for the project was provided by the Wellcome Trust. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",
year = "2020",
month = feb,
day = "1",
doi = "10.1002/humu.23936",
language = "English (US)",
volume = "41",
pages = "449--464",
journal = "Human mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "2",
}